

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21

**Title: A first-in-human clinical study of an intranasal spray of a cocktail containing two synergetic antibodies neutralizes Omicron BA.4/5**

**Authors:**

Xinghai Zhang<sup>1†</sup>, Feiyang Luo<sup>2,3†</sup>, huajun Zhang<sup>1†</sup>, Hangtian Guo<sup>4,7†</sup>, Junhui Zhou<sup>1,5†</sup>, Tingting Li<sup>2,3†</sup>, Shaohong Chen<sup>1,5†</sup>, Shuyi Song<sup>2,3</sup>, Meiyong Shen<sup>6</sup>, Yan Wu<sup>1</sup>, Yan Gao<sup>7,8</sup>, Xiaojian Han<sup>2,3</sup>, Yingming Wang<sup>2,3</sup>, Chao Hu<sup>2,3</sup>, Xiaodong Zhao<sup>9</sup>, Huilin Guo<sup>9</sup>, Dazhi Zhang<sup>9</sup>, Yuchi Lu<sup>7</sup>, Wei Wang<sup>10</sup>, Kai Wang<sup>11</sup>, Ni Tang<sup>11</sup>, Tengchuan Jin<sup>12</sup>, Menglu Ding<sup>13</sup>, Shuhui Luo<sup>13</sup>, Cuicui Lin<sup>13</sup>, Tingting Lu<sup>13</sup>, Bingxia Lu<sup>13</sup>, Yang Tian<sup>13</sup>, Chengyong Yang<sup>13</sup>, Guofeng Cheng<sup>13\*</sup>, Haitao Yang<sup>7,8\*</sup>, Aishun Jin<sup>2,3\*</sup>, Xiaoyun Ji<sup>4,10,14\*</sup>, Rui Gong<sup>1\*</sup>, Sandra Chiu<sup>12\*</sup>, Ailong Huang<sup>11\*</sup>

**Affiliations:**

<sup>1</sup>CAS Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, Hubei 430071, China

<sup>2</sup>Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing 400010, China.

<sup>3</sup>Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing 400010, China.

<sup>4</sup>The State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Institute of Viruses and Infectious Diseases, Chemistry and Biomedicine Innovation Center (ChemBIC), Institute of Artificial Intelligence Biomedicine, Nanjing University, Nanjing 210023, China.

<sup>5</sup>University of Chinese Academy of Sciences, Beijing 100049, China

22 <sup>6</sup>Department of Endocrine Breast Surgery, The First Affiliated Hospital of Chongqing Medical  
23 University, Chongqing 400010, China.

24 <sup>7</sup>Shanghai Institute for Advanced Immunochemical Studies and School of Life Science and  
25 Technology, Shanghai Tech University, Shanghai 201210, China.

26 <sup>8</sup>Shanghai Clinical Research and Trial Center, Shanghai 201210, China

27 <sup>9</sup>The Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China.

28 <sup>10</sup>Institute of Life Sciences, Chongqing Medical University, Chongqing 400010, China.

29 <sup>11</sup>Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), Institute  
30 for Viral Hepatitis, Department of Infectious Diseases, The Second Affiliated Hospital,  
31 Chongqing Medical University, Chongqing, 400010 China.

32 <sup>12</sup>Division of Life Sciences and Medicine, University of Science and Technology of China,  
33 Hefei, Anhui 230026, China

34 <sup>13</sup>Mindao Haoyue Co., Ltd., SQ0042 Lanyuan Hall, No.61 Daxuecheng Middle Road,  
35 Chongqing, 400042 China

36 <sup>14</sup>Engineering Research Center of Protein and Peptide Medicine, Ministry of Education, Nanjing  
37 210023, China.

38 †These authors contributed equally to this work.

39 \*Corresponding authors: Haitao Yang (yanght@shanghaitech.edu.cn), Aishun Jin  
40 (aishunjin@cqmu.edu.cn), Xiaoyun Ji (xiaoyun.ji@nju.edu.cn), Rui Gong (gongr@wh.iov.cn),  
41 Sandra Chiu (qiux@ustc.edu.cn), Ailong Huang (ahuang@cqmu.edu.cn)

42

43 **One Sentence Summary:**

44 An intranasal spray of two synergetic antibodies cocktail neutralizing Omicron BA.4/5 and an  
45 initial clinical evaluation in healthy volunteers.

46

47 **Abstract:**

48 Neutralizing monoclonal antibodies (NAbs) with prophylactic and therapeutic efficacy have  
49 demonstrated fundamental importance in the control of SARS-CoV-2 transmission. However,  
50 their wide application has been largely limited by high cost and inconvenience in administration.  
51 Here, we developed an intranasal spray containing two synergetic human NAbs that could  
52 broadly neutralize the emerging Omicron variants in vitro. A unique synergetic neutralizing  
53 mechanism was identified that the two NAbs bound to exclusive epitopes on the RBD and  
54 structurally compensate each other in blocking the Spike-ACE2 interaction. Importantly, when  
55 given at low dosages for three consecutive days through the intranasal mucosal route, this  
56 cocktail showed significant improvement in the emergency preventive and therapeutic effects in  
57 hamsters challenged with authentic Omicron BA.1. Further, we performed an investigator-  
58 initiated trial in healthy volunteers (ChiCTR2200066525) to study the safety and  
59 pharmacokinetics of the antibody cocktail administrated as nasal spray. The nasal spray is  
60 generally safe and well tolerated without treatment related severe abnormal effects. The antibody  
61 cocktail nasal spray demonstrated nasal concentrations higher than the IC<sub>90</sub> of neutralization  
62 activity against Omicron BA.4/5 even at 24 hours post dosing. Furthermore, nasal samples from  
63 the study subjects demonstrated potent neutralization activity against Omicron BA.4/5 in an ex  
64 vivo pseudovirus neutralization assay. Together, we provide a novel approach for NAb regimens,  
65 a potentially highly effective product with broad applicable perspective in depressing the  
66 infection risk of new epidemic variant and ameliorating the heavy medical burden of hospital.

67

68 **Main Text:**

69 **INTRODUCTION**

70           Since the outburst of COVID-19 in December 2019, SARS-CoV-2 continues to evolve  
71 substantially, acquiring sets of mutations that enhance its transmissibility, infectivity and the  
72 ability to escape natural and acquired immunity (1-3). Contrast to other variants that  
73 preferentially engage in the lungs, Omicron alters the route of viral entry into host cells and is  
74 prompted to replicate in the upper airway (4-6). This causes more asymptomatic infections  
75 contributing to silent spread of the virus and poses substantial difficulties for effective prevention  
76 for the spread of infection (7-9). Omicron and its sub variants exhibit dramatic antigen shift,  
77 which have been shown to render the booster vaccination or recovery sera ineffective and cause  
78 breakthrough infections (10-13). Recent studies further hampered the active immune protection  
79 with evidences of inadequate protection against Omicron sublineages from vaccinated boosters  
80 based on Omicron BA.1 (14-16). Moreover, Paxlovid, a combination of two small molecule  
81 inhibitors recently received emergency authorization for patients at higher risk of critical illness,  
82 failed to prevent close contact infection in family members living with patients (17-19). Thus,  
83 alternative and supplemental prophylactic drugs are now urgently needed to prevent Omicron  
84 infection and subsequently block its transmission in the community (20-22).

85           Passive antibody administration based on neutralizing antibodies (NAbs) have  
86 demonstrated protective efficacy in susceptible individuals with moderated-to-severe immune  
87 compromise or vaccination contraindication, with promising potential in breaking the  
88 transmission chain (23-25). However, the high cost and the inconvenient intramuscular or  
89 intravenous way of administrations have drastically limited its application in broad population  
90 (20, 26, 27). To overcome these practical drawbacks, passive transfer inhibitors through the

91 intranasal mucosal route may be promising approach to prevent the spread of Omicron (28-31).  
92 Antibodies delivery through an inhalant has been shown to facilitate early-stage contact with the  
93 pathogen in the respiratory tract (32-34). This may serve as an applicable platform enabling  
94 NAbs enrichment in the route of viral entry (e.g. nasal cavity and the upper airway), and  
95 overcoming the low and unsatisfying distribution of NAbs at the site of infection when  
96 administered routinely through a systemic route (35-37).

97 Here, we identified an intranasal applicable cocktail with broad neutralizing capability  
98 against Omicron and its sublineages, and determined its synergetic mechanism. We further  
99 investigated the prophylactic and treatment efficacy of this cocktail against Omicron BA.1 in a  
100 hamster model and evaluated its potential capability of the nasal spray convenient for self-  
101 administration to block the infection of BA.4/5 in a first-in-human trial.

## 102 **RESULTS**

### 103 **Broad neutralizing ability of the cocktail containing 58G6 and 55A8**

104 58G6 and 55A8 were two NAbs identified from COVID-19 convalescent patients at early  
105 2019 (31, 38-40). 55A8 could bind to the spike (S) proteins of wide-type SARS-CoV-2 and its  
106 mutational variants, including Omicron BA.1, BA.2 and BA.4/5, as tested by enzyme-linked  
107 immunosorbent assay (ELISA) (fig. S1A and B). Biolayer interferometry (BLI) analysis revealed  
108 that 55A8 exhibited strong binding affinities to the S proteins of SARS-CoV-2, Delta and  
109 Omicron BA.5, and particularly for Omicron BA.1 and BA.2, at sub-picomolar level ( $<10^{-12}$  M)  
110 (fig. S1C). Further, we confirmed that cocktail of 55A8 and 58G6 could neutralize the  
111 pseudoviruses of SARS-CoV-2 variant strains (Fig. 1A, and fig. S2A and B). Interesting, the  
112 cocktail of 58G6 and 55A8 demonstrated obviously synergetic effects against pseudotyped  
113 SARS-CoV-2 variants as well as the authentic Omicron BA.1, with the half inhibition

114 concentration exponentially lower than the currently approved NAbs for the emergence  
115 treatment of COVID-19 (Fig. 1A and B). Therefore, this cocktail consisted of potent neutralizers  
116 58G6 and 55A8 with synergetic potency and breadth against the Omicron variants.

### 117 **Synergetic neutralizing mechanism of this cocktail**

118 To investigate the neutralizing mechanism of the 55A8, we first studied the single-  
119 particle cryo-electron microscopy (cryo-EM) structures of the antigen-binding fragments (Fabs)  
120 of 55A8 in complex with the prefusion Omicron BA.1 S trimer (fig. S3A). In all observed 55A8  
121 Fabs-S complexes, the S trimer adopted a “1-up/2-down” or a “2-up/1-down” conformation (fig.  
122 S3A and B). Superimposition of the down RBD in the structures of the 55A8 Fab-S and ACE2-S  
123 complexes revealed that a 55A8 Fab binding with a down RBD could create a steric clash  
124 between ACE2 and the adjacent up RBDs, while no overlap between the 55A8 Fab and ACE2 on  
125 the same up RBD were observed (Fig. 2A).

126 Next, the cryo-EM structures of the Omicron BA.1 S trimer in complex with the 55A8  
127 and 58G6 Fabs were determined and similar conformation of the BA.1 S trimer were observed  
128 when treated with the NAb-cocktail (fig. S3C). A refinement to an overall resolution of 3.3 Å  
129 showed that the majority of the selected particle images represented a 4-Fab-per-trimer complex,  
130 containing three 55A8 Fabs and one 58G6 (fig. S3D). Specifically, we found that 55A8 and  
131 58G6 Fab simultaneously bound to a single up RBD, which exhibited no conformational changes  
132 comparing with the BA.1 S-55A8 Fab complex (Fig. 2B). The addition of 58G6 occupied the  
133 ACE2 binding site on the 55A8-bound RBD and further occluded the accessibility of the  
134 Omicron BA.1 S protein to ACE2 (Fig. 2C and D). This was further evidenced by the ACE2  
135 competition assay, in which 55A8 showed no competition with ACE2 for binding to the  
136 Omicron BA.1 RBD, but partially competed with ACE2 for binding to the Omicron BA.1 S

137 protein (fig. S4A). Also, we confirmed that 58G6 and 55A8 could simultaneously bind to the S  
138 proteins of SARS-CoV-2, Omicron BA.1 and Omicron BA.2 in a noncompetitive manner (fig.  
139 S4B). These findings suggested that the synergetic neutralization might be achieved through  
140 complementary steric occlusion of ACE2 by the pair of 55A8 and 58G6.

141 To determine the binding epitopes of these NAbs on Omicron BA.1 S proteins, we  
142 assessed the potential hydrogen bonds of 55A8 and 58G6 complementarity determining regions  
143 (CDRs) (fig. S5A to D). Specifically, half of the six (CDRs; CDRH3, CDRL1 and CDRL3) of  
144 the 55A8 Fab were found to directly participate in the interactions with the S<sup>345-352</sup> and S<sup>440-450</sup>  
145 regions (fig. S6A and B). Several potential hydrogen bonds, including R346, Y351, K440, S443,  
146 K444, V445 and N450, were identified at the interface of the 55A8 Fab and Omicron RBD (fig.  
147 S6C). The CDRs of 58G6 were shown to form unique interactions with the mutated amino acids  
148 N477, K478 and R493 within Omicron BA.1 RBM, explaining the sustained neutralizing  
149 capability of this RBM-targeted NAb against the Omicron BA.1 variants (fig. S6D).

### 150 **Intranasal delivery of this cocktail protect hamster from Omicron challenge**

151 The protective efficacy of the cocktail of 55A8 and 58G6 against Omicron BA.1  
152 infection were verified in a hamster model. On Day 0, hamsters received a single intranasal  
153 administration of 1500 µg 58G6, 500 µg 55A8 or combination of 300 µg 55A8 with 1000 µg  
154 58G6 one hour prior to a challenge with 10<sup>4</sup> plaque forming unit (PFU) of Omicron BA.1  
155 through nasal drips (Fig. 3A). Post-infection, two additional NAb(s) treatments were given at day  
156 1 and 2, and the animals were sacrificed one day later (Fig. 3A). RT-qPCR and plaque assays  
157 with harvested trachea and lungs tissues showed that viral RNA copies and infectious virus loads  
158 were significantly reduced (Fig. 3B and C). Importantly, the cocktail treatment resulted in robust



159 viral clearance both in the upper respiratory tract (turbinate and trachea) and lower respiratory  
160 tract (lungs).

161 Further, we investigated the protective efficacy of this cocktail with lower dosages and a  
162 prolonged pretreatment time (Fig. 3D). Significant decrease in the viral RNA copies were found  
163 in the trachea and lung tissues, and the infectious viral load was reduced substantially even with  
164 remarkably low dose of the cocktail treatment (25  $\mu$ g 55A8 + 25  $\mu$ g 58G6) (Fig. 3E and F).  
165 Encouraged by the observed protective effects associated with the cocktail spray, we analyzed  
166 the emergency treatment potential of 55A8 alone and the cocktail at 3 h post-infection (Fig. 3G).  
167 Expectedly, post-infection administration of 55A8 or the cocktail did not affect viral copies  
168 detected in the airway tissues (Fig. 3H). However, 55A8 profoundly impacted successful viral  
169 assembly, indicated by the significant reduction of virus load in both lungs (Fig. 3I). These data  
170 showed that the cocktail of 55A8 and 58G6 could confer protection even at markedly low doses  
171 and displayed a potential applicable value in the emergency treatment through the convenient  
172 administration with intranasal delivery.

### 173 **First-in-human trial of 55A8 and 58G6 antibody cocktail in healthy volunteers**

174 A cocktail of 55A8 and 58G6 at 4:1 mass ratio was selected based on neutralization  
175 activity against Omicron BA.4/5 pseudovirus (Table S1). A formulation of 5 mg/mL total  
176 antibody concentration for the cocktail filled in a nasal spray device for self-administration was  
177 produced under Good Manufacturing Practice (GMP). This 4:1 combination of 55A8 and 58G6  
178 at 5 mg/mL is called “A8G6” antibody cocktail. A8G6 cocktail had studied for preclinical  
179 toxicity in Rhesus monkeys under Good Laboratory Practice (GLP) and no safety concern was  
180 observed. A first-in-human randomized and placebo-controlled trial on the intranasal delivery of  
181 the antibody cocktail was conducted in 108 healthy volunteers (Fig. 4) to assess the

182 safety/tolerability (primary objective) and pharmacokinetics (nasal and serum concentration over  
183 time, secondary objective) of A8G6 nasal spray. The baseline demographic information of the  
184 study subjects is listed in Table S2 and A8G6 versus placebo is 5 to 1 in all cohorts. The trial  
185 started with cohort 1, in which different doses (ranging from one dose to four doses per day)  
186 were given within one day (Fig. 4). In cohort 2, 3 and 4, four doses per day were given for 3, 7  
187 and 14 consecutive days. Overall, A8G6 nasal spray is well tolerated with minimum treatment  
188 related adverse effects (Table S3 and S4) and the primary objective was met.

189         In second objective of the trial, the pharmacokinetics of A8G6 nasal spray was studied to  
190 optimize the dosing regimen. The target concentration is defined as nasal concentration above  
191 BA.4/5 pseudovirus neutralization IC<sub>90</sub>, which is about 5000 ng/mL. The results showed that  
192 after a single dose nasal administration, nasal concentration of A8G6 can maintain above BA.4/5  
193 neutralization IC<sub>90</sub> for 8 hours in > 90% subjects and dropped to below BA.5 IC<sub>90</sub> at 24 hours  
194 post single dose for >50% of subjects (Fig. 5A). This suggests that multiple doses are required to  
195 maintain nasal concentration above BA.4/5 IC<sub>90</sub> throughout the entire day. Similarly, two doses  
196 of nasal spray separated by 4 hours can maintain nasal concentration above IC<sub>90</sub> 8 hours post 2<sup>nd</sup>  
197 dose but cannot provide 24 hours coverage (Fig. 5B). When dosed at 2\*0.7 mg per dose, nasal  
198 concentration of A8G6 was similar to 0.7 mg per dose (Fig. 5A and C). Four doses of A8G6 at 4  
199 hours per dose, however, can achieve nasal concentration above BA.4/5 IC<sub>90</sub> at 24 hours post 1<sup>st</sup>  
200 dose or until the 1<sup>st</sup> dose of next day (Fig. 5D). Collectively, cohort 1 data suggest that higher  
201 dose than 0.7 mg per dose does not result in higher nasal A8G6 concentration; repeat dosing  
202 during the day is required to maintain nasal concentration above the target concentration of  
203 BA.4/5 IC<sub>90</sub>.

204 Since each dose of 0.7 mg can maintain 8 hours coverage above BA.4/5 IC<sub>90</sub>, the dosing  
205 frequency could be changed to 3 doses per day at 8 hours per dose. When dosing for multiple  
206 consecutive days (3, 7 and 14 days), the nasal concentration at the end of the dosing was similar  
207 to day 1, suggesting minimum accumulation of A8G6 in nasal cavity over multiple days of  
208 dosing (Fig. 6A to C). To study the amount of A8G6 cocktail entering systemic blood  
209 circulation, we developed an ELISA assay that can specifically detect 58G6 in human serum  
210 using anti-58G6 specific antibodies. The results showed that for trail subjects in repeat dosing  
211 cohort 3 and 4, the serum 58G6 concentrations are below the detection limit (0.5 ng/mL) at the  
212 beginning and at the end of dosing period. This suggested that A8G6 has minimum penetration  
213 in the systemic blood circulation, which is consistent with the fact that antibody is a large  
214 molecule that has limited permeability through the nasal mucosa. Further, we studied the  
215 pharmacodynamics of A8G6 cocktail nasal spray by testing the nasal samples from the study  
216 subjects for ex vivo neutralization activity against Omicron BA.4/5 (Fig. 7). The results  
217 confirmed more than 90% BA.4/5 neutralization activity in all the samples. This human nasal  
218 pharmacokinetics/pharmacodynamics (PK/PD) data provided a good basis for potential clinical  
219 efficacy of this nasal spray for preventing Omicron BA.5 infections.

## 220 **DISCUSSION**

221 Given the identified rapid loss of protection by vaccination against SARS-CoV-2, the on-  
222 time NAb injection has been shown with timely prophylactic efficacy but has limited range of  
223 application, due to the high cost and inconvenience in administration (20-22). In this study, we  
224 identified two synergetic NAb that could broadly neutralize the emerging Omicron variants.  
225 Synergetic neutralizing mechanism was found to largely rely on a unique complimentary  
226 addition of an RBM-targeted NAb (58G6) to a non-RBM NAb 55A8 to completely occlude

227 ACE2 accessibility, with potential mutual inhibitions for the occurrence of escape mutations  
228 often seen with long-term application (41-43). This might greatly support the current lack of  
229 single NAb in face of Omicron and its sub variants that dramatically escape the majority of  
230 existing SARS-CoV-2 NAbs, and put the cocktail at the center stage for the development of  
231 clinically effective prophylactic regimens against the Omicron pandemic (44).

232 Together with the global attempt to provide affordable and accessible prophylactic drugs,  
233 we have advanced 55A8/58G6 (A8G6) cocktail into animal and human studies and presented the  
234 initial investigation by nasal spraying the NAb cocktail for the possibility of interrupting  
235 Omicron transmission in community (20). As the upper air tract has been shown to be favored by  
236 Omicron, several studies have proved evidences that intranasal pretreatment with small molecule  
237 inhibitor, anti-sense oligonucleotide (ASO) targeting SARS-CoV-2 RNA genome, anti-ACE2  
238 mAb or mini-proteins mimicking hACE2 could effectively reduce respiratory virus replication  
239 and prevent SARS-CoV-2 infection (28, 30, 32, 33, 45, 46). It is evident that our A8G6 nasal  
240 spray antibody works uniquely differently from those nasal delivery molecules, by well-  
241 characterized mechanism of action and specificity, favorable NAb drug properties, or low safety  
242 risk with its local exposure. We further proved that the cocktail we identified could confer  
243 protective efficacy even at a markedly low dose of 50 µg against authentic Omicron BA.1  
244 challenge in the hamster model, suggesting an economic outlook for the medical cost with its  
245 potential wide range applications. Together, all these features of A8G6 nasal spray provide  
246 strong foundation for fast development into clinical studies in human, while to the best of our  
247 knowledge, those other intranasal delivery molecules have not yet advanced into human studies  
248 or the clinical data have yet ready to be disclosed. This will make our study the first published  
249 detailed PK/PD data on a nasal spray of neutralizing antibodies for the potential prevention of

250 Omicron, and the product based on this cocktail are currently undergone further clinical  
251 development to test for its applicable value in the prevention and emergency treatment against  
252 the Omicron pandemic (44).

253         The major challenge that arises with mucosal drug delivery comes from the rapid  
254 physical clearance by the mucociliary system (47). In response, repeated administrations of our  
255 NAb and cocktail have shown with effective long-term protection, which may further reduce the  
256 potential risk of entrapping the virus in the mucosa by virus-antibody complexes. This calls for  
257 excellent biocompatibility with mAb products subjected for repetitive treatment. Hence, we  
258 chose patient-derived NAb with low immunogenicity over other designed proteins or NAb  
259 from other species. In addition, we utilized the IgG subtype of NAb to best restrict potential  
260 undesired immune responses. Although dimerized IgA are released into the upper airways and  
261 may represent elevated protective capacity and optimal on-site pharmacodynamics, IgG exhibit  
262 operational maturation in large-scale preparation with stable quality control between batches and  
263 are better choice for the potential wide range application of the NAb-based nasal spray in  
264 purpose of actual clinical use (32). Also, the fact that IgG is released to the lower lung through  
265 passive transudation may better facilitate the emergency treatment effect of our cocktail. Finally,  
266 the absence of immune response in the first-in-human trial of the cocktail NAb is encouraging  
267 for the concept of using repetitive intranasal protective measurements in the long combat with  
268 continuous emerging SARS-CoV-2 mutational variants.

269         There are a few limitations with our study. First, due to the lag in the availability of  
270 authentic Omicron sublineages variants, in vitro neutralization experiments were performed  
271 against wild-type SARS-CoV-2 and only two mutants, Delta and Omicron BA.1. Future  
272 experiments with updated Omicron sublineages are needed to determine the antiviral activity of

273 our cocktail against the full landscape of the Omicron clade. Second, the physiological  
274 disparities of respiratory systems between human and rodent models raise questions for the  
275 observed preventative effects. Excitingly, as projected based on the faster respiration rate of  
276 rodents, cocktail 55A8/58G6 exhibited more persistent PK in human nasal cavity (Fig. 5A to D)  
277 than in rodents. Certainly, thorough efficacy study in human trials is warranted to validate the  
278 clinical efficacy of this cocktail.

279 In conclusion, we present a potent NAb cocktail against Omicron variants with high  
280 prophylactic efficacy at low dosage, which can be dosed in the self-administrable nasal spray  
281 format. The associated low cost and the needle-free convenience make it acceptable for potential  
282 large-scale application in general population. Our product represents promising passive NAb  
283 interventions that may effectively aid the current prophylactic vaccines to mitigate the current  
284 SARS-CoV-2 transmission and its probable resurgence.

## 285 **MATERIALS AND METHODS**

### 286 **Study design**

287           The ultimate objective of this study was to collect the PK/PD information of an intranasal  
288 spray of a human antibody cocktail A8G6 data in a first-in-human trial. At the outset, human IgG  
289 antibodies with low immunogenicity were applied by means of intranasal spray and tested for the  
290 efficiency of blocking SARS-CoV-2 infection. Specifically, two nAbs (55A8 and 58G6) were  
291 selected from our screening library established before the dominance of Omicron BA.5, with  
292 outstanding neutralizing potency and broad neutralizing ability characterized by BLI affinity  
293 experiments and a standard pseudovirus and authentic virus neutralization assays. The specific  
294 neutralizing mechanism of 55A8 were further assessed by cryoEM. The observed synergetic  
295 neutralizing mechanism of 55A8 and 58G6 was addressed by structure analysis and confirmed  
296 by BLI competition assays of inhibiting RBD-ACE2 and Spike-ACE2 binding.

297           Next, we performed animal studies to determine whether low concentration of intranasal  
298 delivered 55A8 and 58G6 could provide protective efficacy pre- and post-exposure of Omicron  
299 BA.1 infection. Female hamsters (age of five to six weeks) were randomly assigned to groups.  
300 Animal researchers were not blinded to the study groups or during the assessment of the  
301 outcomes. No data points were omitted for the analysis. Sample sizes were determined based on  
302 previous experience. All the animal studies were reviewed and approved by the Institutional  
303 Animal Care and Use Committee of the Institute of Wuhan Institute of Virology, Chinese  
304 Academy of Sciences, and performed in an ABSL-3 facility (WIVA45202104).

305           This first-in-human trial was a randomized, double-blind, placebo-controlled study. A  
306 total of 108 healthy volunteers were enrolled into the study, each provided written informed  
307 consent in according with institutional guidelines. The trial is registered at Chinese Clinical Trial

308 Registry with registration # ChiCTR2200066525. The trial was conducted in accordance with the  
309 Second Affiliated Hospital of Chongqing Medical University (Chongqing, China) Institutional  
310 Ethics Review Board (Study # AY-62-8001). The ethical approval of this trial complies with the  
311 requirements of the Good Clinical Practice, the Declaration of Helsinki of the World Medical  
312 Association, International Ethical Guidelines on Biomedical Research Involving Human Subjects  
313 of the Council for International Organizations of Medical Sciences, and relevant domestic laws  
314 and regulations. The sample size was determined based on precise assess both the primary and  
315 secondary objectives. The primary objective of this clinical study was to evaluate the safety and  
316 tolerance of A8G6 nasal spray under continuous repetitive use. To this end, we recorded the  
317 number of adverse events. The second objective was to evaluate the PK of A8G6 nasal spray to  
318 optimize the dosing regimen.

319 For PK analysis, we collected the blood samples at 1 and 3 days after final dose in cohort 1-3,  
320 and 3 and 7 days after final dose in cohort 4. Nasal swab was collected (□) at 0.25 and 4 hours  
321 after the final dose from left nostril, 4 and 8 hours from right nostril, and day 2 and day 4 from  
322 both nostrils in cohort 1a and 1c (Fig. 5A and 5C); (□) at 0.25 hours before and 4 hours after the  
323 final dose from left nostril, 4 and 8 hours after the final dose from right nostril, and day 2 and  
324 day 4 from both nostrils in cohort 1b and 1d (Fig. 5B and 5D); (□) at 0.5 hours before 2<sup>nd</sup> dose  
325 on day 1 and 12 hours after last dose from left nostril, 0.5 hours before and 24 hours after last  
326 dose from right nostril, and day 6 from both nostrils in cohort 2 (Fig. 6A); (□) at 0.5 hours  
327 before 2<sup>nd</sup> dose on day 1 and 12 hours after last dose from left nostril, 0.5 hours before and 24  
328 hours after last dose from right nostril, and day 10 from both nostrils in cohort 3 (Fig. 6B); (□) at  
329 0.5 hours before 2<sup>nd</sup> dose on day 1, 15 mins before and 1 hours after last dose, and day 16 from  
330 left nostril, 0.5 hours before 2<sup>nd</sup> dose on day 8, 4 and 12 hours after last dose from right nostril,



331 and day 17 and 21 from both nostrils in cohort 4 (Fig. 6C). The concentrations of A8G6 from  
332 these samples were predicted by an ELISA assay containing a pair of specific anti-58G6  
333 antibodies, and the corresponding neutralization activities of collected samples were measured  
334 using an Omicron BA.5 pseudovirus neutralization assay. An independent data safety monitoring  
335 committee performed trial oversight and made recommendations after review of safety  
336 reports between cohorts. Full details of the trial design, conduct, oversight and sample analysis  
337 and statistical analysis were provided in the protocol, which is available in the supplemental  
338 data.**Statistical methods**

339 Statistical analyses of the animal studies were performed using GraphPad Prism software  
340 v.9.2.0. Comparisons between two groups were performed using unpaired Student's t tests.  
341 Comparisons among multiple groups were performed using one-way ANOVA followed by  
342 Tukey's multiple comparison post hoc test.  $P \leq 0.05$  was considered significant (significance  
343 is denoted as follows: \* $P \leq 0.05$ , \*\* $P \leq 0.01$ , \*\*\* $P \leq 0.001$ , and \*\*\*\* $P \leq 0.0001$ ).

#### 344 **List of Supplementary Materials**

##### 345 **Materials and Methods**

346 Figs. S1 to S6

347 Tables S1 to S5

348 A8G6 IIT Protocol

349 References (48–60)

##### 350 **References and Notes**

- 351 1. P. Mlcochova, S. A. Kemp, M. S. Dhar, G. Papa, B. Meng, I. Ferreira, R. Datir, D. A. Collier, A. Albecka,  
352 S. Singh, R. Pandey, J. Brown, J. Zhou, N. Goonawardane, S. Mishra, C. Whittaker, T. Mellan, R. Marwal,

- 353 M. Datta, S. Sengupta, K. Ponnusamy, V. S. Radhakrishnan, A. Abdullahi, O. Charles, P. Chattopadhyay,  
354 P. Devi, D. Caputo, T. Peacock, C. Wattal, N. Goel, A. Satwik, R. Vaishya, M. Agarwal, A. Mavousian, J.  
355 H. Lee, J. Bassi, C. Silacci-Fegni, C. Saliba, D. Pinto, T. Irie, I. Yoshida, W. L. Hamilton, K. Sato, S.  
356 Bhatt, S. Flaxman, L. C. James, D. Corti, L. Piccoli, W. S. Barclay, P. Rakshit, A. Agrawal, R. K. Gupta,  
357 SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. *Nature* **599**, 114-119 (2021).
- 358 2. P. Wang, M. S. Nair, L. Liu, S. Iketani, Y. Luo, Y. Guo, M. Wang, J. Yu, B. Zhang, P. D. Kwong, B. S.  
359 Graham, J. R. Mascola, J. Y. Chang, M. T. Yin, M. Sobieszczyk, C. A. Kyratsous, L. Shapiro, Z. Sheng, Y.  
360 Huang, D. D. Ho, Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. *Nature* **593**, 130-135  
361 (2021).
- 362 3. P. Wang, R. G. Casner, M. S. Nair, M. Wang, J. Yu, G. Cerutti, L. Liu, P. D. Kwong, Y. Huang, L.  
363 Shapiro, D. D. Ho, Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. *Cell host &*  
364 *microbe* **29**, 747-751.e744 (2021).
- 365 4. B. Meng, A. Abdullahi, I. Ferreira, N. Goonawardane, A. Saito, I. Kimura, D. Yamasoba, P. P. Gerber, S.  
366 Fatihi, S. Rathore, S. K. Zepeda, G. Papa, S. A. Kemp, T. Ikeda, M. Toyoda, T. S. Tan, J. Kuramochi, S.  
367 Mitsunaga, T. Ueno, K. Shirakawa, A. Takaori-Kondo, T. Brevini, D. L. Mallery, O. J. Charles, J. E.  
368 Bowen, A. Joshi, A. C. Walls, L. Jackson, D. Martin, K. G. C. Smith, J. Bradley, J. A. G. Briggs, J. Choi,  
369 E. Madissoon, K. B. Meyer, P. Mlcochova, L. Ceron-Gutierrez, R. Doffinger, S. A. Teichmann, A. J.  
370 Fisher, M. S. Pizzuto, A. de Marco, D. Corti, M. Hosmillo, J. H. Lee, L. C. James, L. Thukral, D. Veessler,  
371 A. Sigal, F. Sampaziotis, I. G. Goodfellow, N. J. Matheson, K. Sato, R. K. Gupta, Altered TMPRSS2 usage  
372 by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. *Nature* **603**, 706-714 (2022).
- 373 5. H. Zhao, L. Lu, Z. Peng, L. L. Chen, X. Meng, C. Zhang, J. D. Ip, W. M. Chan, A. W. Chu, K. H. Chan, D.  
374 Y. Jin, H. Chen, K. Y. Yuen, K. K. To, SARS-CoV-2 Omicron variant shows less efficient replication and  
375 fusion activity when compared with Delta variant in TMPRSS2-expressed cells. *Emerging microbes &*  
376 *infections* **11**, 277-283 (2022).
- 377 6. K. P. Y. Hui, J. C. W. Ho, M. C. Cheung, K. C. Ng, R. H. H. Ching, K. L. Lai, T. T. Kam, H. Gu, K. Y. Sit,  
378 M. K. Y. Hsin, T. W. K. Au, L. L. M. Poon, M. Peiris, J. M. Nicholls, M. C. W. Chan, SARS-CoV-2  
379 Omicron variant replication in human bronchus and lung ex vivo. *Nature* **603**, 715-720 (2022).
- 380 7. T. Carvalho, Silent spread. *Nature medicine* **26**, 1807 (2020).

- 381 8. N. Garrett, A. Tapley, J. Andriesen, I. Seocharan, L. H. Fisher, L. Bunts, N. Espy, C. L. Wallis, A. K.  
382 Randhawa, N. Ketter, M. Yacovone, A. Goga, L. G. Bekker, G. E. Gray, L. Corey, High Rate of  
383 Asymptomatic Carriage Associated with Variant Strain Omicron. *medRxiv : the preprint server for health*  
384 *sciences*, (2022).
- 385 9. N. Garrett, A. Tapley, J. Andriesen, I. Seocharan, L. H. Fisher, L. Bunts, N. Espy, C. L. Wallis, A. K.  
386 Randhawa, M. D. Miner, N. Ketter, M. Yacovone, A. Goga, Y. Huang, J. Hural, P. Kotze, L. G. Bekker, G.  
387 E. Gray, L. Corey, High Asymptomatic Carriage with the Omicron Variant in South Africa. *Clinical*  
388 *infectious diseases : an official publication of the Infectious Diseases Society of America*, (2022).
- 389 10. N. Andrews, E. Tessier, J. Stowe, C. Gower, F. Kirsebom, R. Simmons, E. Gallagher, S. Thelwall, N.  
390 Groves, G. Dabrera, R. Myers, C. N. J. Campbell, G. Amirthalingam, M. Edmunds, M. Zambon, K. Brown,  
391 S. Hopkins, M. Chand, S. N. Ladhani, M. Ramsay, J. Lopez Bernal, Duration of Protection against Mild  
392 and Severe Disease by Covid-19 Vaccines. *The New England journal of medicine* **386**, 340-350 (2022).
- 393 11. N. Andrews, J. Stowe, F. Kirsebom, S. Toffa, R. Sachdeva, C. Gower, M. Ramsay, J. Lopez Bernal,  
394 Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and  
395 death in England. *Nature medicine* **28**, 831-837 (2022).
- 396 12. T. K. Burki, Omicron variant and booster COVID-19 vaccines. *The Lancet. Respiratory medicine* **10**, e17  
397 (2022).
- 398 13. C. Kuhlmann, C. K. Mayer, M. Claassen, T. Maponga, W. A. Burgers, R. Keeton, C. Riou, A. D.  
399 Sutherland, T. Suliman, M. L. Shaw, W. Preiser, Breakthrough infections with SARS-CoV-2 omicron  
400 despite mRNA vaccine booster dose. *Lancet (London, England)* **399**, 625-626 (2022).
- 401 14. S. A. Costa Clemens, L. Weckx, R. Clemens, A. V. Almeida Mendes, A. Ramos Souza, M. B. V. Silveira,  
402 S. N. F. da Guarda, M. M. de Nobrega, M. I. de Moraes Pinto, I. G. S. Gonzalez, N. Salvador, M. M.  
403 Franco, R. N. de Avila Mendonça, I. S. Queiroz Oliveira, B. S. de Freitas Souza, M. Fraga, P. Aley, S.  
404 Bibi, L. Cantrell, W. Dejnirattisai, X. Liu, J. Mongkolsapaya, P. Supasa, G. R. Screaton, T. Lambe, M.  
405 Voysey, A. J. Pollard, Heterologous versus homologous COVID-19 booster vaccination in previous  
406 recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority,  
407 single blind, randomised study. *Lancet (London, England)* **399**, 521-529 (2022).

- 408 15. C. J. Reynolds, C. Pade, J. M. Gibbons, A. D. Otter, K. M. Lin, D. Muñoz Sandoval, F. P. Pieper, D. K.  
409 Butler, S. Liu, G. Joy, N. Forooghi, T. A. Treibel, C. Manisty, J. C. Moon, A. Semper, T. Brooks, Á.  
410 McKnight, D. M. Altmann, R. J. Boyton, H. Abbass, A. Abiodun, M. Alfarihi, Z. Alldis, D. M. Altmann, O.  
411 E. Amin, M. Andiapen, J. Artico, J. B. Augusto, G. L. Baca, S. N. L. Bailey, A. N. Bhuva, A. Boulter, R.  
412 Bowles, R. J. Boyton, O. V. Bracken, B. O'Brien, T. Brooks, N. Bullock, D. K. Butler, G. Captur, O. Carr,  
413 N. Champion, C. Chan, A. Chandran, T. Coleman, J. Couto de Sousa, X. Couto-Parada, E. Cross, T.  
414 Cutino-Moguel, S. D'Arcangelo, R. H. Davies, B. Douglas, C. Di Genova, K. Dieobi-Anene, M. O. Diniz,  
415 A. Ellis, K. Feehan, M. Finlay, M. Fontana, N. Forooghi, S. Francis, J. M. Gibbons, D. Gillespie, D. Gilroy,  
416 M. Hamblin, G. Harker, G. Hemingway, J. Hewson, W. Heywood, L. M. Hickling, B. Hicks, A. D.  
417 Hingorani, L. Howes, I. Itua, V. Jardim, W. J. Lee, M. Jensen, J. Jones, M. Jones, G. Joy, V. Kapil, C.  
418 Kelly, H. Kurdi, J. Lambourne, K. M. Lin, S. Liu, A. Lloyd, S. Louth, M. K. Maini, V. Mandadapu, C.  
419 Manisty, Á. McKnight, K. Menacho, C. Mfuko, K. Mills, S. Millward, O. Mitchelmore, C. Moon, J. Moon,  
420 D. Muñoz Sandoval, S. M. Murray, M. Noursadeghi, A. Otter, C. Pade, S. Palma, R. Parker, K. Patel, M.  
421 Pawarova, S. E. Petersen, B. Piniera, F. P. Pieper, L. Rannigan, A. Rapala, C. J. Reynolds, A. Richards, M.  
422 Robathan, J. Rosenheim, C. Rowe, M. Royds, J. Sackville West, G. Sambile, N. M. Schmidt, H. Selman,  
423 A. Semper, A. Seraphim, M. Simion, A. Smit, M. Sugimoto, L. Swadling, S. Taylor, N. Temperton, S.  
424 Thomas, G. D. Thornton, T. A. Treibel, A. Tucker, A. Varghese, J. Veerapen, M. Vijayakumar, T. Warner,  
425 S. Welch, H. White, T. Wodehouse, L. Wynne, D. Zahedi, B. Chain, J. C. Moon, Immune boosting by  
426 B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. *Science (New York, N.Y.)*, eabq1841  
427 (2022).
- 428 16. Y. Cao, A. Yisimayi, F. Jian, W. Song, T. Xiao, L. Wang, S. Du, J. Wang, Q. Li, X. Chen, Y. Yu, P. Wang,  
429 Z. Zhang, P. Liu, R. An, X. Hao, Y. Wang, J. Wang, R. Feng, H. Sun, L. Zhao, W. Zhang, D. Zhao, J.  
430 Zheng, L. Yu, C. Li, N. Zhang, R. Wang, X. Niu, S. Yang, X. Song, Y. Chai, Y. Hu, Y. Shi, L. Zheng, Z.  
431 Li, Q. Gu, F. Shao, W. Huang, R. Jin, Z. Shen, Y. Wang, X. Wang, J. Xiao, X. S. Xie, BA.2.12.1, BA.4 and  
432 BA.5 escape antibodies elicited by Omicron infection. *Nature*, (2022).
- 433 17. E. Mahase, Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company  
434 reports. *BMJ (Clinical research ed.)* **375**, n2713 (2021).
- 435 18. T. Burki, The future of Paxlovid for COVID-19. *The Lancet. Respiratory medicine*, (2022).

- 436 19. D. Phizackerley, Three more points about Paxlovid for covid-19. *BMJ (Clinical research ed.)* **377**, o1397  
437 (2022).
- 438 20. D. The Lancet Infectious, Unmet need for COVID-19 therapies in community settings. *The Lancet.  
439 Infectious diseases* **21**, 1471 (2021).
- 440 21. E. Dolgin, The race for antiviral drugs to beat COVID - and the next pandemic. *Nature* **592**, 340-343  
441 (2021).
- 442 22. E. J. Rubin, L. R. Baden, S. Morrissey, Audio Interview: A Potential New Agent to Treat Covid-19. *The  
443 New England journal of medicine* **385**, e101 (2021).
- 444 23. M. J. Levin, A. Ustianowski, S. De Wit, O. Launay, M. Avila, A. Templeton, Y. Yuan, S. Seegobin, A.  
445 Ellery, D. J. Levinson, P. Ambery, R. H. Arends, R. Beavon, K. Dey, P. Garbes, E. J. Kelly, G. Koh, K. A.  
446 Near, K. W. Padilla, K. Psachoulia, A. Sharbaugh, K. Streicher, M. N. Pangalos, M. T. Esser,  
447 Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19. *The New England journal  
448 of medicine* **386**, 2188-2200 (2022).
- 449 24. Y. M. Loo, P. M. McTamney, R. H. Arends, M. E. Abram, A. A. Aksyuk, S. Diallo, D. J. Flores, E. J.  
450 Kelly, K. Ren, R. Roque, K. Rosenthal, K. Streicher, K. M. Tuffy, N. J. Bond, O. Cornwell, J. Bouquet, L.  
451 I. Cheng, J. Duniyak, Y. Huang, A. I. Rosenbaum, V. Pilla Reddy, H. Andersen, R. H. Carnahan, J. E.  
452 Crowe, Jr., A. I. Kuehne, A. S. Herbert, J. M. Dye, H. Bright, N. L. Kallewaard, M. N. Pangalos, M. T.  
453 Esser, The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates  
454 and has an extended half-life in humans. *Science translational medicine* **14**, eabl8124 (2022).
- 455 25. R. Stuver, G. L. Shah, N. S. Korde, L. E. Roeker, A. R. Mato, C. L. Batlevi, D. J. Chung, S. Doddi, L.  
456 Falchi, B. Gyurkocza, A. Hamilton, Y. H. Lin, A. A. Jakubowski, E. Joffe, H. L. Landau, R. J. Lin, S.  
457 Mailankody, M. L. Palomba, J. H. Park, M. A. Perales, D. M. Ponce, L. V. Ramanathan, G. A. Salles, M.  
458 Scordo, S. K. Seo, U. A. Shah, E. M. Stein, D. Straus, S. Z. Usmani, J. W. Young, A. D. Zelenetz, A. Noy,  
459 S. A. Vardhana, Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients  
460 with hematologic malignancies. *Cancer cell* **40**, 590-591 (2022).
- 461 26. R. Rubin, Questions Remain About Who Will Get Monoclonal Antibodies for COVID-19 Preexposure  
462 Prophylaxis. *Jama* **327**, 207-208 (2022).

- 463 27. R. Rubin, Monoclonal Antibodies for COVID-19 Preexposure Prophylaxis Can't Come Fast Enough for  
464 Some People. *Jama* **326**, 1895-1897 (2021).
- 465 28. A. C. Hunt, J. B. Case, Y. J. Park, L. Cao, K. Wu, A. C. Walls, Z. Liu, J. E. Bowen, H. W. Yeh, S. Saini, L.  
466 Helms, Y. T. Zhao, T. Y. Hsiang, T. N. Starr, I. Goreshnik, L. Kozodoy, L. Carter, R. Ravichandran, L. B.  
467 Green, W. L. Matochko, C. A. Thomson, B. Vögeli, A. Krüger, L. A. VanBlargan, R. E. Chen, B. Ying, A.  
468 L. Bailey, N. M. Kafai, S. E. Boyken, A. Ljubetič, N. Edman, G. Ueda, C. M. Chow, M. Johnson, A.  
469 Addetia, M. J. Navarro, N. Panpradist, M. Gale, Jr., B. S. Freedman, J. D. Bloom, H. Ruohola-Baker, S. P.  
470 J. Whelan, L. Stewart, M. S. Diamond, D. Veessler, M. C. Jewett, D. Baker, Multivalent designed proteins  
471 neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice. *Science*  
472 *translational medicine* **14**, eabn1252 (2022).
- 473 29. W. Fan, S. Sun, N. Zhang, Y. Zhang, P. Jiao, J. Wang, G. F. Gao, W. Liu, Y. Bi, L. Yang, Nasal delivery of  
474 thermostable and broadly neutralizing antibodies protects mice against SARS-CoV-2 infection. *Signal*  
475 *transduction and targeted therapy* **7**, 55 (2022).
- 476 30. J. Ou, Y. Zhang, Y. Wang, Z. Zhang, H. Wei, J. Yu, Q. Wang, G. Wang, B. Zhang, C. Wang, ACE2-  
477 Targeting antibody suppresses SARS-CoV-2 Omicron and Delta variants. *Signal transduction and targeted*  
478 *therapy* **7**, 43 (2022).
- 479 31. X. Zhang, H. Zhang, T. Li, S. Chen, F. Luo, J. Zhou, P. Zheng, S. Song, Y. Wu, T. Jin, N. Tang, A. Jin, C.  
480 Yang, G. Cheng, R. Gong, S. Chiu, A. Huang, A potent neutralizing antibody provides protection against  
481 SARS-CoV-2 Omicron and Delta variants via nasal delivery. *Signal transduction and targeted therapy* **7**,  
482 301 (2022).
- 483 32. Z. Ku, X. Xie, P. R. Hinton, X. Liu, X. Ye, A. E. Muruato, D. C. Ng, S. Biswas, J. Zou, Y. Liu, D. Pandya,  
484 V. D. Menachery, S. Rahman, Y. A. Cao, H. Deng, W. Xiong, K. B. Carlin, J. Liu, H. Su, E. J. Haanes, B.  
485 A. Keyt, N. Zhang, S. F. Carroll, P. Y. Shi, Z. An, Nasal delivery of an IgM offers broad protection from  
486 SARS-CoV-2 variants. *Nature* **595**, 718-723 (2021).
- 487 33. X. Wu, L. Cheng, M. Fu, B. Huang, L. Zhu, S. Xu, H. Shi, D. Zhang, H. Yuan, W. Nawaz, P. Yang, Q. Hu,  
488 Y. Liu, Z. Wu, A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via  
489 intranasal administration. *Cell reports* **37**, 109869 (2021).

- 490 34. H. A. Parray, S. Shukla, R. Perween, R. Khatri, T. Shrivastava, V. Singh, P. Murugavelu, S. Ahmed, S.  
491 Samal, C. Sharma, S. Sinha, K. Luthra, R. Kumar, Inhalation monoclonal antibody therapy: a new way to  
492 treat and manage respiratory infections. *Applied microbiology and biotechnology* **105**, 6315-6332 (2021).
- 493 35. E. Bequignon, C. Dhommée, C. Angely, L. Thomas, M. Bottier, E. Escudier, D. Isabey, A. Coste, B. Louis,  
494 J. F. Papon, V. Gouilleux-Gruart, FcRn-Dependent Transcytosis of Monoclonal Antibody in Human Nasal  
495 Epithelial Cells In Vitro: A Prerequisite for a New Delivery Route for Therapy? *International journal of*  
496 *molecular sciences* **20**, (2019).
- 497 36. Y. Al Ojaimi, T. Blin, J. Lamamy, M. Gracia, A. Pitiot, C. Denevault-Sabourin, N. Joubert, J. P. Pouget, V.  
498 Gouilleux-Gruart, N. Heuzé-Vourc'h, D. Lanznaster, S. Poty, T. Sécher, Therapeutic antibodies - natural  
499 and pathological barriers and strategies to overcome them. *Pharmacology & therapeutics* **233**, 108022  
500 (2022).
- 501 37. J. T. Sockolosky, M. R. Tiffany, F. C. Szoka, Engineering neonatal Fc receptor-mediated recycling and  
502 transcytosis in recombinant proteins by short terminal peptide extensions. *Proceedings of the National*  
503 *Academy of Sciences of the United States of America* **109**, 16095-16100 (2012).
- 504 38. X. Han, Y. Wang, S. Li, C. Hu, T. Li, C. Gu, K. Wang, M. Shen, J. Wang, J. Hu, R. Wu, S. Mu, F. Gong,  
505 Q. Chen, F. Gao, J. Huang, Y. Long, F. Luo, S. Song, S. Long, Y. Hao, L. Li, Y. Wu, W. Xu, X. Cai, Q.  
506 Gao, G. Zhang, C. He, K. Deng, L. Du, Y. Nai, W. Wang, Y. Xie, D. Qu, A. Huang, N. Tang, A. Jin, A  
507 Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2.  
508 *Frontiers in immunology* **12**, 653189 (2021).
- 509 39. T. Li, X. Han, C. Gu, H. Guo, H. Zhang, Y. Wang, C. Hu, K. Wang, F. Liu, F. Luo, Y. Zhang, J. Hu, W.  
510 Wang, S. Li, Y. Hao, M. Shen, J. Huang, Y. Long, S. Song, R. Wu, S. Mu, Q. Chen, F. Gao, J. Wang, S.  
511 Long, L. Li, Y. Wu, Y. Gao, W. Xu, X. Cai, D. Qu, Z. Zhang, H. Zhang, N. Li, Q. Gao, G. Zhang, C. He,  
512 W. Wang, X. Ji, N. Tang, Z. Yuan, Y. Xie, H. Yang, B. Zhang, A. Huang, A. Jin, Potent SARS-CoV-2  
513 neutralizing antibodies with protective efficacy against newly emerged mutational variants. *Nature*  
514 *communications* **12**, 6304 (2021).
- 515 40. F. Gao, J. Huang, T. Li, C. Hu, M. Shen, S. Mu, F. Luo, S. Song, Y. Hao, W. Wang, X. Han, C. Qian, Y.  
516 Wang, R. Wu, L. Li, S. Li, A. Jin, A Highly Conserved Peptide Vaccine Candidate Activates Both

- 517 Humoral and Cellular Immunity Against SARS-CoV-2 Variant Strains. *Frontiers in immunology* **12**,  
518 789905 (2021).
- 519 41. R. Rockett, K. Basile, S. Maddocks, W. Fong, J. E. Agius, J. Johnson-Mackinnon, A. Arnott, S. Chandra,  
520 M. Gall, J. Draper, E. Martinez, E. M. Sim, C. Lee, C. Ngo, M. Ramsperger, A. N. Ginn, Q. Wang, M.  
521 Fennell, D. Ko, H. L. Lim, N. Gilroy, M. V. N. O'Sullivan, S. C. Chen, J. Kok, D. E. Dwyer, V.  
522 Sintchenko, Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use. *The New England*  
523 *journal of medicine* **386**, 1477-1479 (2022).
- 524 42. Z. Ku, X. Xie, E. Davidson, X. Ye, H. Su, V. D. Menachery, Y. Li, Z. Yuan, X. Zhang, A. E. Muruato, I. E.  
525 AG, B. Tyrell, K. Doolan, B. J. Doranz, D. Wrapp, P. F. Bates, J. S. McLellan, S. R. Weiss, N. Zhang, P.  
526 Y. Shi, Z. An, Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2  
527 escape. *Nature communications* **12**, 469 (2021).
- 528 43. S. T. Sonnleitner, M. Prelog, S. Sonnleitner, E. Hinterbichler, H. Halbfurter, D. B. C. Kopecky, G.  
529 Almanzar, S. Koblmüller, C. Sturmbauer, L. Feist, R. Horres, W. Posch, G. Walder, Cumulative SARS-  
530 CoV-2 mutations and corresponding changes in immunity in an immunocompromised patient indicate viral  
531 evolution within the host. *Nature communications* **13**, 2560 (2022).
- 532 44. D. Li, G. D. Sempowski, K. O. Saunders, P. Acharya, B. F. Haynes, SARS-CoV-2 Neutralizing Antibodies  
533 for COVID-19 Prevention and Treatment. *Annual review of medicine* **73**, 1-16 (2022).
- 534 45. T. Shapira, I. A. Monreal, S. P. Dion, D. W. Buchholz, B. Imbiakha, A. D. Olmstead, M. Jager, A. Désilets,  
535 G. Gao, M. Martins, T. Vandal, C. A. H. Thompson, A. Chin, W. D. Rees, T. Steiner, I. R. Nabi, E.  
536 Marsault, J. Sahler, D. G. Diel, G. R. Van de Walle, A. August, G. R. Whittaker, P. L. Boudreault, R.  
537 Leduc, H. C. Aguilar, F. Jean, A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and  
538 therapeutic. *Nature* **605**, 340-348 (2022).
- 539 46. C. Zhu, J. Y. Lee, J. Z. Woo, L. Xu, X. Nguyenla, L. H. Yamashiro, F. Ji, S. B. Biering, E. Van Dis, F.  
540 Gonzalez, D. Fox, E. Wehri, A. Rustagi, B. A. Pinsky, J. Schaletzky, C. A. Blish, C. Chiu, E. Harris, R. I.  
541 Sadreyev, S. Stanley, S. Kauppinen, S. Rouskin, A. M. Näär, An intranasal ASO therapeutic targeting  
542 SARS-CoV-2. *Nature communications* **13**, 4503 (2022).
- 543 47. M. Ibrahim, R. Verma, L. Garcia-Contreras, Inhalation drug delivery devices: technology update. *Medical*  
544 *devices (Auckland, N.Z.)* **8**, 131-139 (2015).



- 545 48. P. Zhou, X. L. Yang, X. G. Wang, B. Hu, L. Zhang, W. Zhang, H. R. Si, Y. Zhu, B. Li, C. L. Huang, H. D.  
546 Chen, J. Chen, Y. Luo, H. Guo, R. D. Jiang, M. Q. Liu, Y. Chen, X. R. Shen, X. Wang, X. S. Zheng, K.  
547 Zhao, Q. J. Chen, F. Deng, L. L. Liu, B. Yan, F. X. Zhan, Y. Y. Wang, G. F. Xiao, Z. L. Shi, A pneumonia  
548 outbreak associated with a new coronavirus of probable bat origin. *Nature* **579**, 270-273 (2020).
- 549 49. H. Guo, Y. Gao, T. Li, T. Li, Y. Lu, L. Zheng, Y. Liu, T. Yang, F. Luo, S. Song, W. Wang, X. Yang, H. C.  
550 Nguyen, H. Zhang, A. Huang, A. Jin, H. Yang, Z. Rao, X. Ji, Structures of Omicron spike complexes and  
551 implications for neutralizing antibody development. *Cell reports* **39**, 110770 (2022).
- 552 50. I. Kimura, Y. Kosugi, J. Wu, J. Zahradnik, D. Yamasoba, E. P. Butlertanaka, Y. L. Tanaka, K. Uriu, Y.  
553 Liu, N. Morizako, K. Shirakawa, Y. Kazuma, R. Nomura, Y. Horisawa, K. Tokunaga, T. Ueno, A. Takaori-  
554 Kondo, G. Schreiber, H. Arase, C. Motozono, A. Saito, S. Nakagawa, K. Sato, The SARS-CoV-2 Lambda  
555 variant exhibits enhanced infectivity and immune resistance. *Cell reports* **38**, 110218 (2022).
- 556 51. S. Zhao, H. Zhang, X. Yang, H. Zhang, Y. Chen, Y. Zhan, X. Zhang, R. Jiang, M. Liu, L. Liu, L. Chen, W.  
557 Tang, C. Peng, X. Gao, Z. Zhang, Z. Shi, R. Gong, Identification of potent human neutralizing antibodies  
558 against SARS-CoV-2 implications for development of therapeutics and prophylactics. *Nature*  
559 *communications* **12**, 4887 (2021).
- 560 52. D. N. Mastrorarde, Automated electron microscope tomography using robust prediction of specimen  
561 movements. *J Struct Biol* **152**, 36-51 (2005).
- 562 53. S. Q. Zheng, E. Palovcak, J.-P. Armache, K. A. Verba, Y. Cheng, D. A. Agard, MotionCor2: anisotropic  
563 correction of beam-induced motion for improved cryo-electron microscopy. *Nature Methods* **14**, 331-332  
564 (2017).
- 565 54. A. Punjani, J. L. Rubinstein, D. J. Fleet, M. A. Brubaker, cryoSPARC: algorithms for rapid unsupervised  
566 cryo-EM structure determination. *Nature Methods* **14**, 290-296 (2017).
- 567 55. E. F. Pettersen, T. D. Goddard, C. C. Huang, G. S. Couch, D. M. Greenblatt, E. C. Meng, T. E. Ferrin,  
568 UCSF Chimera-A visualization system for exploratory research and analysis. *Journal of Computational*  
569 *Chemistry* **25**, 1605-1612 (2004).
- 570 56. L. A. Kelley, S. Mezulis, C. M. Yates, M. N. Wass, M. J. E. Sternberg, The Phyre2 web portal for protein  
571 modeling, prediction and analysis. *Nature Protocols* **10**, 845-858 (2015).

- 572 57. P. Emsley, B. Lohkamp, W. G. Scott, K. Cowtan, Features and development of Coot. *Acta*  
573 *Crystallographica Section D* **66**, 486-501 (2010).
- 574 58. D. Liebschner, P. V. Afonine, M. L. Baker, G. Bunkoczi, V. B. Chen, T. I. Croll, B. Hintze, L.-W. Hung, S.  
575 Jain, A. J. McCoy, N. W. Moriarty, R. D. Oeffner, B. K. Poon, M. G. Prisant, R. J. Read, J. S. Richardson,  
576 D. C. Richardson, M. D. Sammito, O. V. Sobolev, D. H. Stockwell, T. C. Terwilliger, A. G. Urzhumtsev,  
577 L. L. Videau, C. J. Williams, P. D. Adams, Macromolecular structure determination using X-rays, neutrons  
578 and electrons: recent developments in Phenix. *Acta Crystallographica Section D* **75**, 861-877 (2019).
- 579 59. L. Feng, Q. Wang, C. Shan, C. Yang, Y. Feng, J. Wu, X. Liu, Y. Zhou, R. Jiang, P. Hu, An adenovirus-  
580 vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques. *Nature*  
581 *communications* **11**, 1-11 (2020).
- 582 60. Y. N. Zhang, X. D. Li, Z. R. Zhang, H. Q. Zhang, B. Zhang, A mouse model for SARS-CoV-2 infection by  
583 exogenous delivery of hACE2 using alphavirus replicon particles. *Cell Research*, 1-3 (2020).

584

585

586 **Acknowledgments:**

587 We thank the Center for Animal Experiment and BSL-3 laboratory, Wuhan Institute of Virology,  
588 Chinese Academy of Sciences; Center for Biosafety Mega-Science, Chinese Academy of  
589 Sciences; and the National Virus Resource Center for resource support.

590 **Funding:**

591 The Natural Science Foundation of Hubei Province of China (2019CFA076)

592 The National Natural Science Foundation of China (32170949, 81871639, 92169109, 81871656  
593 and 8181101099)

594 The National Science and Technology Major Project (2017ZX10202203)

595 The National Key Research and Development Program of China (2018YFA0507100 and  
596 2016YFD0500300);

597 Guangzhou National Laboratory (SRPG22-015)

598 Lingang Laboratory (LG202101-01-07)

599 Science and Technology Commission of Shanghai Municipality (YDZX20213100001556 and  
600 20XD1422900).

601 The first-in-human Investigator Initiated Study was funded by the Emergency Project from the  
602 Science & Technology Commission of Chongqing (cstc2021jscx-fyzzX0001)

603 **Author contributions:**

604 A.H., S.C., A.J., H.Y., C.G. and C.Y. conceived and designed the project. For biological function  
605 analysis of the NAbs, F.L., T.L., M.S., X.H., Y.W. and C.H. screened and cloned the antibodies,  
606 and expressed and purified the antibodies; F.L., T.L. and W.W. were responsible for BLI assays  
607 for the binding ability, affinity, and the competition experiment of NAbs; F.L., T.L., S.S., K.W.,  
608 N.T., M.D., and S. L. prepared various pseudovirus and conducted the pseudovirus neutralization  
609 assays. For the efficacy test of the NAbs *in vitro* and *in vivo*, X.Z., H.Z., J.Z., S.C., Y.W. and  
610 R.G. performed authentic SARS-CoV-2 neutralization assays and animal experiments. For  
611 structure analysis, H.G. and Y.L. cloned, expressed and purified Omicron BA.1 S proteins; H.G.,  
612 Y.G., and Y.L. collected, processed the cryo-EM data, and built and refined the structure model;  
613 X.J., H.Y. and T.J. analyzed and discussed the cryo-EM data. A.H., M.D., S.L., C.L., T.L., B.L.,  
614 Y.T., C.Y., and G.C. designed and supported the investigator-initiated trial. A. H., S.C., A.J.,  
615 X.J., R.G., X.Z. and F.L., Y.T., G.C. wrote the manuscript. All authors revised and reviewed the  
616 final manuscript.


617 **Competing interests:**

618 Ailong Huang and Aishun Jin declare the following competing interests: Patent has been filed for  
619 some of the antibodies presented here (patent application number: PCT/CN2020/115480,  
620 PCT/CN2021/078150, PCT/CN2021/113261; patent applicants: Chongqing Medical University).  
621 All other authors declare no competing interests.

622 **Data and materials availability:**


623 The coordinates and cryo-EM map files for the 55A8-BA.1 S complexes and 55A8/58G6-BA.1  
 624 S complexes have been deposited in the Protein Data Bank (PDB) under accession number  
 625 7WWI, 7WWJ, 7WWK, 7XJ6, 7XJ8 and 7XJ9. All other data are available from the  
 626 corresponding author upon reasonable request.

627 **Figures**



628  
 629 **Fig. 1. The cocktail of 58G6 and 55A8 broadly neutralizing Omicron emerging variants. (A)**  
 630 The neutralizing potencies of 58G6, 55A8 and cocktail of 58G6 and 55A8 against SARS-CoV-2,


631 Omicron BA.1, BA.1.1, BA.2, BA.2.12.1 and BA.5 variants were measured with a pseudovirus  
 632 neutralization assay. The dashed line indicates a 0% or 50% reduction in viral neutralization.  
 633 Data for each NAb were obtained from a representative neutralization experiment of two  
 634 replicates, presented as mean values  $\pm$  SEM. **(B)** Neutralization against authentic SARS-CoV-2,  
 635 Delta and Omicron BA.1 viruses.



636

637 **Fig. 2. Synergetic neutralizing mechanism of the cocktail of 58G6 and 55A8. (A)**

638 Superposition of the locally refined Omicron RBD-ACE2 (PDB ID: 7WSA) model together with  
 639 the locally refined Omicron RBD-55A8 Fab model. **(B)** Locally refined model of the 55A8 Fab  
 640 and 58G6 Fab on the same up Omicron RBD. HC, heavy chain; LC, light chain. **(C)** 55A8 Fabs  
 641 bind to Omicron S trimers in 2 states. Two perpendicular views of Omicron BA.1 S-55A8  
 642 complexes are shown as the surface. **(D)** 55A8 and 58G6 Fabs simultaneously bind to Omicron S  
 643 trimers in 2 states. Two perpendicular views of Omicron S-55A8/58G6 complexes are shown as  
 644 the surface. 55A8 heavy chain: salmon, 55A8 light chain: pink, 58G6 heavy chain: navy, 58G6  
 645 light chain: sky blue, three Omicron RBDs: different shades of purple.




647 **Fig. 3. Intranasal delivery of cocktail of 55A8 and 58G6 protect hamster from Omicron**  
648 **challenge.** Syrian golden hamsters challenged with  $10^4$  PFU of Omicron were treated with 58G6,  
649 55A8 or the two-antibody cocktail at 1 h or 3 hrs pre-infection, or 3 hrs post-infection, and two  
650 additional treatments at 24 and 48 h post-infection. The turbinates, trachea and lungs were  
651 harvested on day 3 post-treatment and analyzed by viral RNA and infectious virus (by qRT-PCR  
652 and PFU/g). (A), (D) and (G) Animal experimental scheme. (B), (E) and (H) Viral RNA  
653 ( $\log_{10}$ (RNA copies per g)) was detected in the respiratory tract of hamsters (C), (F) and (I) The  
654 infectious viruses (PFU) in the respiratory tract was measured with a viral plaque assay  
655 performed with Vero E6 cells.

<b>Cohort 1a (N=12)</b>	<b>Single day: 1 dose of 0.7 mg</b>
<b>Cohort 1b (N=12)</b>	<b>Single day: 2 dose of 0.7 mg; 4 hours per dose</b>
<b>Cohort 1c (N=12)</b>	<b>Single day: 2 dose of 0.7 mg; dose together</b>
<b>Cohort 1d (N=12)</b>	<b>Single day: 4 dose of 0.7 mg; 4 hours per dose</b>
<b>Cohort 2 (N=12)</b>	<b>Three days: 4 dose of 0.7 mg; 4 hours per dose</b>
<b>Cohort 3 (N=12)</b>	<b>Seven days: 4 dose of 0.7 mg; 4 hours per dose</b>
<b>Cohort 4 (N=36)</b>	<b>Fourteen days: 4 dose of 0.7 mg; 4 hours per dose</b>

656  
657 **Fig. 4. Trial design for first-in-human study of 55A8/58G6 (A8G6) nasal spray**  
658 **neutralization antibody cocktail.** A total of 108 healthy volunteers were enrolled in 4 cohorts  
659 of study. A8G6: Placebo = 5:1 for each cohort. Cohort 1 has 4 sub-cohorts, which focused on the  
660 study of different doses (1, 2, 4 doses) within one day of dosing. Cohort 2 to 4 focused on 4  
661 doses per day over 3, 7 and 14 days, respectively.





662

663 **Fig. 5. Cohort 1 clinical study of 55A8/58G6 (A8G6) cocktail showed nasal NABs**

664 **concentration above the  $IC_{90}$  neutralization activity on Omicron BA.4/5.**

665 **concentration above the  $IC_{90}$  neutralization activity on Omicron BA.4/5.**

666 In each sub-cohort (1a, 1b, 1c, and 1d), 12 healthy volunteers were given different doses of


667 cocktail NABs (each dose is 560  $\mu$ g of 55A8 plus 140  $\mu$ g of 58G6, total 0.7 mg per dose) to both

668 left and right nostril. A8G6 nasal spray: placebo nasal spray = 10:2. After A8G6 nasal spray, 5

669 volunteers took nasal samples at 0.25 hour post last dose at the left nostril, and at 1 hour post last

670 dose at the right nostril; the other 5 took nasal samples at 4 hours post last dose at the left nostril

671 and at 8 hours at the right nostril; 24 hours and 72 hours after 1<sup>st</sup> dose, all 10 volunteers took the  
 672 nasal swab at both left and right nostril. Nasal swab (containing ~50  $\mu$ L of nasal surface mucus)  
 673 was washed in 500  $\mu$ L PBS buffer before testing for A8G6 concentration using ELISA assay.  
 674 Nasal A8G6 concentration was predicted from A8G6 PBS wash concentration by multiple a  
 675 dilution factor of 11. Omicron BA.4/5 pseudovirus neutralization IC<sub>90</sub> and IC<sub>99</sub> values were  
 676 labeled as dashed line and dash/dot line, respectively. X-axis label legend of Cohort 1a: D-1 L is  
 677 the day before dosing; D1<sup>1st+15min</sup> L is day 1 15 minutes after 1<sup>st</sup> dose left nostril nasal swab;  
 678 D1<sup>1st+1h</sup> L is day 1 1 hour after 1<sup>st</sup> dose left nostril nasal swab; D1<sup>1st+4h</sup> R is day 1 4 hours after 1<sup>st</sup>  
 679 dose right nostril nasal swab; D1<sup>1st+8h</sup> R is day 1 8 hours after 1<sup>st</sup> dose right nostril nasal swab;  
 680 D2 L is 24 hours after day 1 1<sup>st</sup> dose left nostril swab; D2 R is 24 hours after day 1 1<sup>st</sup> dose right  
 681 nostril swab; D4 L is 72 hours after day 1 1<sup>st</sup> dose left nostril swab; D4 R is 72 hours after day 1  
 682 1<sup>st</sup> dose right nostril swab. X-axis label nomenclature of other Cohorts is similar to cohort 1a.




684 **Fig. 6. Cohort 2-4 clinical study of 55A8/58G6 (A8G6) cocktail showed nasal NAb**  
 685 **concentration above the IC<sub>90</sub> neutralization activity on Omicron BA.4/5.**

686 In cohort 2-4, healthy volunteers were given 4 doses of cocktail NAb (each dose is 560  $\mu$ g of  
 687 55A8 plus 140  $\mu$ g of 58G6, total 0.7 mg per dose) per day over 3, 7 and 14 days, respectively.

688 A8G6 nasal spray: placebo nasal spray = 10: 2. After A8G6 nasal spray, 5 volunteers took nasal

689 samples in alternate nostrils at each time point during dosing period, for a total of 4 time points  
690 that account for total of 10 volunteers. During the follow up period, all 10 volunteers took the  
691 nasal swab at both left and right nostril. Nasal swab (containing ~50  $\mu$ L of nasal surface mucus)  
692 was washed in 500  $\mu$ L PBS buffer before testing for A8G6 concentration using ELISA assay.  
693 Nasal A8G6 concentration was predicted from A8G6 PBS wash concentration by multiple a  
694 dilution factor of 11. Omicron BA.4/5 pseudovirus neutralization  $IC_{90}$  and  $IC_{99}$  values were  
695 labeled as dashed line and dash/dot line, respectively. X-axis label nomenclature is similar to  
696 Fig. 5.



698 **Fig.7. Selected nasal swab samples from cohort 1a and 1d showed > 90% neutralization**  
699 **activity on Omicron BA.4/5.**

700 Selected nasal samples from cohort 1a and cohort 1d were checked for BA.4/5 neutralization  
701 activities using a pseudovirus neutralization assay. Nasal samples were first diluted 11-fold in  
702 PBS then diluted 10-fold in cell culture media to measure their neutralization activities; the final  
703 neutralization activities in the original nasal samples were calculated by fitting a standard dose  
704 response curve.

705

706

707